We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals

45 hedge funds and large institutions have $3.11M invested in Actinium Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

13% more funds holding

Funds holding: 40 → 45 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

6.83% less ownership

Funds ownership: 15.46% → 8.63% (-6.8%)

86% less capital inflows, than outflows

Capital inflows: $413K | Capital outflows: $2.92M

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
45
Holders Change
+5
Holders Change %
+12.5%
% of All Funds
0.88%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
7
Reduced
7
Closed
7
Calls
–
Puts
$1​K
Net Calls
-⁠$1​K
Net Calls Change
-⁠$1​K

ATNM Hedge Fund Activity: Q4 2019 in Review

45 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2019, worth a combined $3.11M — down 46% from $5.79M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ATNM positions and 7 closed out — a net gain of 5 holders — while 7 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock, adding an estimated $161K. The largest seller was Sio Capital Management, exiting entirely with an estimated $1.38M sold.

  • 45 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2019, up from 40 in Q3 2019.
  • Funds reported $3.11M of Actinium Pharmaceuticals stock for Q4 2019, down 46% quarter-over-quarter.
  • 12 funds opened new Actinium Pharmaceuticals positions in Q4 2019 and 7 closed out, a net change of +5 holders.
  • The largest Actinium Pharmaceuticals buyer in Q4 2019 was BlackRock, an estimated $161K added.
  • The largest Actinium Pharmaceuticals seller in Q4 2019 was Sio Capital Management, an estimated $1.38M sold.

Based on aggregated 13F filings for Q4 2019.